Thus, we speculated that miR-497 might be correlated with trastuzumab-induced cardiotoxicity via interacting with FGF-23 in HER2-positive breast cancer patients treated with neoadjuvant treatment. The gene discussed is FGF23; the disease is breast carcinoma.